Power vacuum, Alzheimer's trials fuelling Biogen takeover rumours
But analysts remain sceptical Merck & Co and Allergan will actually make an offer for the drugmaker
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Washington
ON July 21, as Biogen chief executive officer George Scangos announced he would step down, he floated the idea that his company might buy rivals to cement its place near the top of the booming field of biotechnology. Today, Biogen looks more like prey than predator.
Conjecture that the company, a frequent target of rumours in the mergers and acquisitions world, may be acquired increased following a Wall Street Journal report that Merck & Co and Allergan have each considered a takeover. Shares of Biogen spiked in New York on Tuesday, though the Journal said that the talks were informal and preliminary. All three companies declined to comment.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
